



February 1, 2017 (CVS)

## Immune System with a Timer

**Press release: Scientists from the German Cancer Research Center and the Heidelberg University Hospital have discovered a previously unknown feedback mechanism of the human immune system. Their research shows how the innate immune system is quickly activated in the case of a viral infection, but is inhibited after just a few hours. This prevents an excessive immune reaction that might result in cell damage. The results of the study have been published in the journal “Molecular Cell.”**

If viruses such as influenza or Hepatitis C viruses infect a cell, the innate immune system of the human body reacts immediately: It releases chemical messengers which alert the surrounding cells, trigger an inflammatory response and activate the adaptive immune system. Heidelberg researchers have now discovered a mechanism that eventually inhibits the defensive response and therefore prevents long term cell damage and possible autoimmune diseases: A sensor for infections with so-called RNA-viruses is the receptor RIG-I (*retinoic acid inducible gene 1*), which recognizes the genome of the virus according to its specific structure, then binds with it and triggers defensive reactions to it. About 8 hours after the infection, RIG-I triggers its own adversary: DAPK1 (*death associated protein kinase 1*), an already familiar enzyme, which – as the name suggests – functions destructively. The enzyme deactivates RIG-I, so it cannot recognize RNA-viruses any longer. The defense is inhibited. Dr. Marco Binder – former fellow of the Medical Faculty of Heidelberg at the Center for Infectiology and current leader of a research group at the DKFZ – published the results of his research group in the journal “Molecular Cell.”

Interestingly, this regulatory mechanism has a timer of sorts, which ensures that the RIG-I can initially lead the defense against the viruses without being inhibited. Using influenza viruses which infect human cells, this current study showed that DAPK1 only became activated about 8 hours after the initial infection. “As soon as DAPK1 is fully active, we see how the antiviral defense program is slowly shut down. In the course of our research, we were able to show that this was not just a random correlation, but rather that the two are causally linked,” said Dr. Marco Binder. Without this kind of counter-regulation of the body, there could be an excessive release of chemical messengers by the immune system, which could lead to cell damaging inflammation and long term auto immune diseases.

## Hepatitis C Infection and Liver Cancer: DAPK1 could facilitate Tumor Growth

These new findings may help indicate why a chronic infection with Hepatitis C viruses leads to liver cancer for some patients. Hepatitis C viruses are able to trick the body’s immune system and permanently settle in liver cells. The sensor RIG-I stays active throughout and could in this way permanently activate DAPK1. “Current studies show that with certain very aggressive tumors an activation of DAPK1 greatly facilitates tumor growth,” summarized Dr. Marco Binder. “If, during a chronic Hepatitis C infection, the constant, latent activation of DAPK1 coincides with a specific genetic defect, then it is as if one adds fuel to the fire.” In the future, researchers want to clarify whether there might be a correlation with a defect in

the p53 gene - also known as the “guardian of the genome” - which is responsible for repairing DNA.

The Heidelberg researchers achieved their discovery by deactivating all 719 known human kinase genes in human cell cultures one after another. They then noted that the kinase DAPK1 measurably slows down the cell's program by transferring a phosphate group to RIG-I. The phosphorylation deactivates the RIG-I and the viruses can multiply unchecked.

**Literature:**

Willemsen et al. (2017): Phosphorylation-Dependent Feedback Inhibition of RIG-I by DAPK1 Identified by Kinome-wide siRNA Screening. *Molecular Cell* 2017. <http://dx.doi.org/10.1016/j.molcel.2016.12.021>

**Further information on the internet:**

<http://www.dkfz.de/de/virus-assoziierte-karzinogenese/groups/AGBinder/index.html>

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

**Contact:**

Dr. Stefanie Seltmann  
Head of Press and Public Relations  
German Cancer Research Center  
Im Neuenheimer Feld 280  
D-69120 Heidelberg  
T: +49 6221 42 2854  
F: +49 6221 42 2968  
[presse@dkfz.de](mailto:presse@dkfz.de)

Dr. Sibylle Kohlstädt  
Press and Public Relations  
German Cancer Research Center  
Im Neuenheimer Feld 280  
D-69120 Heidelberg  
T: +49 6221 42 2843  
F: +49 6221 42 2968  
Email: [presse@dkfz.de](mailto:presse@dkfz.de)